Differentiate between benign hyperplasia and early-stage cancer. Determine the most appropriate treatment strategy based on genetic findings. Monitor high-risk patients susceptible to gynecological tumors.

Women diagnosed with atypical endometrial hyperplasia. Patients suspected of having early-stage endometrial cancer. Individuals with a family history of genetic tumor syndromes.

Book PTEN Gene Mutation Test | Lahalak Medical Platform

PTEN gene testing provides critical insights into uterine health, helping distinguish between hyperplasia and early-stage cancer to ensure accurate diagnosis and personalized treatment plans for high-risk patients.

Scientific name: PTEN Gene Mutation Analysis for Endometrial Tumors

An advanced molecular test analyzing PTEN gene mutations. It differentiates atypical hyperplasia from early-stage endometrial cancer, facilitating precise diagnosis and effective management strategies for uterine health and oncology.

PTEN Gene Mutation Analysis for Endometrial Tumors - Secure Your Uterine Health

Service type Genetic Laboratory Analysis

Duration 15-20 minutes

Fasting Fasting is not required

Included Services

Sample Collection
Molecular Gene Analysis
Laboratory Results Report

Medical Service Information

Purpose of the Test

Differentiate between benign hyperplasia and early-stage cancer.
Determine the most appropriate treatment strategy based on genetic findings.
Monitor high-risk patients susceptible to gynecological tumors.

Target Groups

Women diagnosed with atypical endometrial hyperplasia.
Patients suspected of having early-stage endometrial cancer.
Individuals with a family history of genetic tumor syndromes.

Frequently Asked Questions

Does the test require blood or tissue? It is typically performed on a tissue biopsy as requested by the physician.
How long do results take? Results are usually available within 7 to 10 working days.